Q2 2026 13F · SEC CIK 2054410
Acorn Capital Advisors, LLC
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $366.5M
- Reported positions
- 20
- Holdings vs S&P 500, 3 yrs
- —
- Assets under management
- $355.3M
Acorn Capital Advisors, LLC is a hedge fund that reported 20 positions worth $366.5M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Cg Oncology Inc (CGON, 21.9%), Urogen Pharma Ltd (URGN, 16.8%), Trevi Therapeutics Inc (TRVI, 10.9%).
Acorn Capital Advisors, LLC holdings all 20 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| CGONCg Oncology Inc | 21.9% | +0.1% | $80.4M |
| URGNUrogen Pharma Ltd | 16.8% | +0.0% | $61.6M |
| TRVITrevi Therapeutics Inc | 10.9% | +0.0% | $40.0M |
| CADLCandel Therapeutics Inc | 9.8% | +0.0% | $36.0M |
| PBYIPuma Biotechnology Inc | 9.1% | +0.0% | $33.5M |
| 008064206Jade Biosciences Inc | 6.0% | +25.4% | $21.9M |
| BCAXBicara Therapeutics Inc | 5.2% | -0.0% | $19.1M |
| KPTIKaryopharm Therapeutics Inc | 4.0% | +427.4% | $14.8M |
| OKUROnkure Therapeutics Inc | 3.5% | +0.0% | $12.9M |
| 23256X407Cybin Inc | 2.8% | +0.0% | $10.2M |
| TARAProtara Therapeutics Inc | 1.8% | +0.0% | $6.7M |
| AURAAura Biosciences Inc | 1.8% | +56.0% | $6.6M |
| LONALeonabio Inc | 1.6% | +0.0% | $5.8M |
| VSTMVerastem Inc | 1.5% | +0.0% | $5.6M |
| AADIWhitehawk Therapeutics Inc | 1.4% | +0.0% | $5.2M |
| QTTBQ32 Bio Inc | 0.8% | -31.4% | $2.8M |
| ENGNEngene Therapeutics Inc | 0.6% | — | $2.2M |
| JSPRJasper Therapeutics Inc | 0.2% | +1.9% | $604K |
| BCABBioatla Inc | 0.1% | -98.0% | $448K |
| VYNEVyne Therapeutics Inc | 0.0% | +0.0% | $926.00 |
What Acorn Capital Advisors, LLC bought and sold in Q2 2026, against Q1 2026.
New positions
- ENGN Engene Therapeutics Inc0.6% of 13F
Added to
- KPTI Karyopharm Therapeutics Inc+427.4% shares
- AURA Aura Biosciences Inc+56.0% shares
- Jade Biosciences Inc+25.4% shares
Reduced
- BCAB Bioatla Inc-98.0% shares
- QTTB Q32 Bio Inc-31.4% shares
Sold out
- TERN Terns Pharmaceuticals Incwas 26.2%
- CRDF Cardiff Oncology Incwas 0.8%
- XFOR X4 Pharmaceuticals, Inc.was 0.3%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +126.2% /yr
- S&P 500 +20.1%
- 3 years
- —
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $366.5M | 20 |
| Q1 2026 | $351.8M | 22 |
| Q4 2025 | $295.1M | 21 |
| Q3 2025 | $197.0M | 20 |
| Q2 2025 | $152.9M | 21 |
| Q1 2025 | $149.9M | 22 |
| Q4 2024 | $185.8M | 21 |
Questions about Acorn Capital Advisors, LLC's portfolio
What stocks does Acorn Capital Advisors, LLC own?
Acorn Capital Advisors, LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 20 positions worth $366.5M. The largest are Cg Oncology Inc (CGON) at 21.9%, Urogen Pharma Ltd (URGN) at 16.8%, Trevi Therapeutics Inc (TRVI) at 10.9%, Candel Therapeutics Inc (CADL) at 9.8% and Puma Biotechnology Inc (PBYI) at 9.1%.
What did Acorn Capital Advisors, LLC buy last quarter?
In Q2 2026, Acorn Capital Advisors, LLC added a new position in Engene Therapeutics Inc (ENGN), Karyopharm Therapeutics Inc (KPTI) (+427.4% shares), Aura Biosciences Inc (AURA) (+56.0% shares) and Jade Biosciences Inc (+25.4% shares), compared with its Q1 2026 filing.
What did Acorn Capital Advisors, LLC sell last quarter?
In Q2 2026, Acorn Capital Advisors, LLC sold all of Terns Pharmaceuticals Inc (TERN), sold all of Cardiff Oncology Inc (CRDF), sold all of X4 Pharmaceuticals, Inc. (XFOR), Bioatla Inc (BCAB) (-98.0% shares) and Q32 Bio Inc (QTTB) (-31.4% shares), compared with its Q1 2026 filing.
When is Acorn Capital Advisors, LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. Acorn Capital Advisors, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Acorn Capital Advisors, LLC manage?
Acorn Capital Advisors, LLC reported $355.3M of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $366.5M.